The judge said he didn't follow the correct procedure for what is effectively a move to deny patients care.

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

To own Recursion, you have to believe its AI driven platform can turn early clinical assets and pharma collaborations into durable, less partnership dependent revenue, while managing heavy cash burn.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...